ArticlePoultry science2026
Effects of a mycotoxin deactivator in broilers exposed to subclinical doses of fumonisins and deoxynivalenol.
Article in Poultry science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Feed ingredients used in poultry production are frequently co-contaminated with multiple mycotoxins, posing challenges that conventional binders alone may not offer comprehensive mycotoxin mitigation. Hence, this study evaluated the efficacy of mycotoxin deactivator, Biofix Select® with FUMzyme® (a multi-component mycotoxin deactivator) on growth performance, antioxidant activity, immune response, and cecal microbiota in broilers exposed to fumonisin (FBs) and deoxynivalenol (DON). A total of 360 one-day-old broiler chicks were randomly distributed in a 2 × 2 factorial design. The dietary treatments were: control, FBs + DON (8.5 mg FBs + 3.9 mg DON per kg of feed), Mycotoxin (MTX) Deactivator (0.1 % Biofix Select® with FUMzyme®), and FBs + DON + MTX Deactivator (0.1 % Biofix Select® with FUMzyme®) (n=6). Data were analyzed using two-way ANOVA. No interaction effects were observed for overall growth performance. However, significant interaction effects between FBs + DON exposure and MTX Deactivator supplementation were observed for gut morphology on d21, with the MTX Deactivator mitigating the reductions in villus length and crypt depth induced by FBs + DON (p < 0.05). On d35, interaction effects were observed in jejunal occludin (OCC) mRNA expression, with the MTX Deactivator counteracting the FBs + DON-induced downregulation of OCC (p < 0.05). On d35, interactions were detected in the percentages of CD8+ T cells and CD8+:CD4+ T cell ratios in the cecal tonsil and spleen (p < 0.05), with MTX Deactivator alleviating the immunosuppression caused by FBs + DON. A significant interaction was also observed in splenic TGF-β mRNA expression, where the MTX Deactivator decreased the TGF-β mRNA expression in birds exposed to FBs + DON (p < 0.05). In conclusion, the MTX Deactivator at 0.1 % mitigated the adverse effects resulting from continuous exposure to subclinical levels of combined FBs and DON in broilers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.